Drug Trial Radar · NCT04373785
NG101m Adjuvant Therapy in Glioblastoma Patients
Last checked: Nov 19, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
52
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Jul 30, 2030
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- NeuGATE TheranosticsIndustry
- Sponsor type
- Industry
- First posted
- May 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the addition of NG101m adjuvant therapy to standard of care treatment of glioblastoma multiforme. All subjects will receive NG101m capsules along with the standard treatment of temozolomide and radiation.
Conditions
- Glioblastoma Multiforme
Interventions
Intensity-modulated radiation therapyRadiation
Intensity-modulated radiation therapy (IMRT) in daily fractions of 2.67 Gy given 5 days per week for 3 weeks, for a total of 40.05 Gy.
TemozolomideDrug
Oral temozolomide (75 mg/m2), given 5 days per week, for 3 weeks during radiotherapy. 1 month after the discontinuation of radiotherapy, oral temozolomide is restarted at 150 to 200 mg/m2 for 5 days during each 28-day cycle for 12 cycles.
NG101mDrug
Oral NG101m capsule continuously twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events and serious adverse eventsTime frame: 1 month
- Efficacy of NG101m adjuvant chemoradiation therapy assessed by measuring 2-year overall survival rate.Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yvonne Kew MD, PLLC
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.